|
DSM AND CRUCELL ANNOUNCE NEW CEO AND ESTABLISHMENT OF PER.C6 R&D CENTER IN BOSTON AREA
28 June 2006 - DSM Coating Resins
| Dutch biotechnology company Crucell N.V. and its technology partner DSM Biologics BV, a business unit of Royal DSM N.V., announced today that Dr. Marco Cacciuttolo has accepted the position of Chief Executive Officer of their joint PER.C6 R&D Center, which will be located in Cambridge, MA. Dr. Cacciuttolo joins the venture with over ten years of experience in technical operations within the biotech and pharmaceutical industries. |
Dr. Cacciuttolo has occupied positions of increasing responsibility at MedImmune, Inc, and most recently at Medarex, Inc. as the Vice President of Technical Operations. Dr. Cacciuttolo received his Ph.D. in Biochemical Engineering from the University of Maryland, Baltimore County and his B.S. in Biochemical Engineering from the Catholic University of Valparaiso, Valparaiso, Chile. The Cambridge, Massachusetts location for the R&D center was specifically selected due to its outstanding scientific resources and world-class talent pool. “We are delighted to bring Marco Cacciuttolo on board as CEO. He has a strong track record in the biotech industry, and will provide strong leadership to the technology venture,” says Dr. Leendert Staal, President and CEO of DSM Pharmaceutical Products. “We are excited with the move to the Boston area, which marks an important next step in the development of our joint venture with Crucell.” The new R&D center will specialize in the further development of the PER.C6 human cell line to make it the premier system for the expression of recombinant pharmaceutical proteins. This center of excellence will provide a fully integrated technology platform, and true turn-key solutions for the production of pharmaceutical proteins, to the biotech industry and the scientific community. This PER.C6 technology platform will comprise cell line generation technology, tailored cell culture media, fermentation processes, equipment design, scale-up, technology transfer, and regulatory support. The R&D center will have dedicated space for PER.C6 users to experience the technology hands on. Dr. Marco Cacciuttolo, Chief Executive Officer of the R&D Center, stated, " I welcome the opportunity to strengthen the technological possibilities that PER.C6 offers to the entire biotechnology industry as a premier expression system for fully human proteins.” Ronald Brus, Managing Director and CEO of Crucell, states: “We are excited about the choice of location. Not only are we building on and adding to the depth and strength of bio-sciences in the Boston area, but this is a major milestone in supporting the growing number of licensees for PER.C6.” The fit-out of the new center will take place over the coming months. Recruitment of some 50 scientific and support staff has started and commencement of operations is expected before the end of 2006.
http://www.dsm.com/en_US/html/dcr/home.htm
About: DSM Coating Resins
DSM Coating Resins is one of the business groups making up DSM’s Performance Materials cluster. It specializes in the development, manufacture and sale of resins for coating systems. It is a global supplier of polyester resins for powder coatings, can coatings and coil coatings. The company also plays an important role as a resins supplier to the decorative coatings market, protective and maintenance coatings market, and industrial coatings markets. DSM Coating Resins has production sites in many countries in Europe, North America and Asia.DSM's activities are grouped into three clusters: Life Science Products, Performance Materials and Industrial Chemicals. DSM Nutritional Products will remain a seperate entity for the time being. The group has annual sales (pro forma, including the recent acquisition - renamed DSM Nutritional Products) of approximately EUR 8 billion and employs in the region of 25 000 people around the world. Its headquarters are based in The Netherlands.
|
More News:
For June 2006
From DSM Coating Resins
For Powder Coatings
|